https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-502011-11-16 00:00:002021-11-15 16:57:44Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-15 / Cancer Lett. 2012 Apr;317(1):56-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-15 / Cancer Lett. 2012 Apr;317(1):56-642011-11-15 00:00:002011-11-15 00:00:00Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-07 / World Neurosurg 2012 May-Jun;77(5-6):736-44
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-07 / World Neurosurg 2012 May-Jun;77(5-6):736-442011-11-07 00:00:002019-02-15 08:46:33Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-02 / J. Immunol. 2011 Dec;187(11):6130-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-02 / J. Immunol. 2011 Dec;187(11):6130-422011-11-02 00:00:002019-02-15 08:40:01Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-01 / Anticancer Res. 2011 Nov;31(11):3963-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-01 / Anticancer Res. 2011 Nov;31(11):3963-72011-11-01 00:00:002019-02-15 08:39:19Tumor response and negative distal resection margins of rectal cancer after hyperthermochemoradiation therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-01 / Anticancer Res. 2011 Nov;31(11):3995-4005
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-01 / Anticancer Res. 2011 Nov;31(11):3995-40052011-11-01 00:00:002019-02-15 08:46:01Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-26 / J. Biomed. Biotechnol. 2011;2011:718710
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-26 / J. Biomed. Biotechnol. 2011;2011:7187102011-10-26 00:00:002019-02-15 09:21:34Safety and clinical usage of newcastle disease virus in cancer therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-22 / Cancer Immunol. Immunother. 2012 May;61(5):629-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-22 / Cancer Immunol. Immunother. 2012 May;61(5):629-412011-10-22 00:00:002019-02-15 08:52:17Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-20 / J Transl Med 2011 Oct;9:178
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-20 / J Transl Med 2011 Oct;9:1782011-10-20 00:00:002019-02-15 08:50:33Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-18 / Int. Immunopharmacol. 2011 Dec;11(12):2200-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-18 / Int. Immunopharmacol. 2011 Dec;11(12):2200-72011-10-18 00:00:002019-02-15 08:47:45Improved efficacy of therapeutic vaccination with dendritic cells pulsed with tumor cell lysate against hepatocellular carcinoma by introduction of 2 tandem repeats of microbial HSP70 peptide epitope 407-426 and OK-432